公开(公告)号：US20170306419A1

公开(公告)日：2017-10-26

申请号：US15638135

申请日：2017-06-29

申请人： Genentech, Inc.

发明人： Thomas E. Januario ,  David Shames

IPC分类号： C12Q1/68 ,  A61K31/517

CPC分类号： C12Q1/6886 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156

摘要： The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.

公开(公告)号：US11674962B2

公开(公告)日：2023-06-13

申请号：US16041363

申请日：2018-07-20

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： Craig Anthony Cummings ,  Yan Li ,  Sarah Margaret Shagan ,  Erica Beth Schleifman ,  David Shames ,  David Fabrizio ,  Daniel Lieber ,  Geoffrey Alan Otto ,  Mark Kennedy ,  Travis Clark ,  Doron Lipson ,  Jie He ,  Shan Zhong

IPC分类号： C12Q1/68 ,  C12Q1/6883 ,  G01N33/574 ,  C07K16/28 ,  G16H50/50 ,  G16H50/30 ,  G16H50/70 ,  G16H50/20 ,  A61P35/00 ,  G06F16/28 ,  C07K14/735 ,  A61K39/00

CPC分类号： G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

摘要： The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US10240207B2

公开(公告)日：2019-03-26

申请号：US15272283

申请日：2016-09-21

申请人： Genentech, Inc.

发明人： Wei Yu ,  David Shames ,  Hartmut Koeppen ,  See Phan ,  Sandra Rost

IPC分类号： C12Q1/6886 ,  C07K16/22 ,  C07K16/28 ,  A61K39/00

摘要： The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US11300570B2

公开(公告)日：2022-04-12

申请号：US16371589

申请日：2019-04-01

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC分类号： G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20190219586A1

公开(公告)日：2019-07-18

申请号：US16371589

申请日：2019-04-01

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC分类号： G01N33/574 ,  A61P35/00 ,  C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  C12Q1/6886 ,  A61K39/395 ,  A61K38/17 ,  A61P35/04

CPC分类号： G01N33/57492 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55 ,  A61P35/00 ,  A61P35/04 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70596 ,  G01N2800/52

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20130259867A1

公开(公告)日：2013-10-03

申请号：US13835532

申请日：2013-03-15

申请人： GENENTECH, INC.

发明人： Lukas Amler ,  David Shames

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/76

摘要： The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.

摘要翻译： 本申请描述了使用NRG1过表达作为治疗HER3抑制剂（例如双特异性HER3 / EGFR抑制剂）的癌症患者的选择标准，以及治疗这些患者的方法。

公开(公告)号：US20200024670A1

公开(公告)日：2020-01-23

申请号：US16591253

申请日：2019-10-02

申请人： Genentech, Inc.

发明人： Thomas E. Januario ,  David Shames

IPC分类号： C12Q1/6886 ,  A61K31/517

摘要： The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.

公开(公告)号：US20150086543A1

公开(公告)日：2015-03-26

申请号：US14551528

申请日：2014-11-24

申请人： Genentech, Inc.

发明人： Thomas E. Januario ,  David Shames

IPC分类号： C12Q1/68 ,  A61K31/517

CPC分类号： C12Q1/6886 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156

摘要： The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.

摘要翻译： 本发明提供了基于ERBB2基因的甲基化状态来预测对癌症治疗的反应的方法。 本发明的一个方面提供了一种基于ERBB2基因的甲基化状态预测对EGFR抑制剂治疗的应答​​的方法。

公开(公告)号：US20130084287A1

公开(公告)日：2013-04-04

申请号：US13630363

申请日：2012-09-28

申请人： Genentech, Inc.

发明人： David Shames ,  Thomas M. Holcomb ,  Kimberly Walter

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6827 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/154

摘要： The present invention provides methods for determining epithelial and mesenchymal phenotype of tumors and predicting whether tumor growth will be sensitive or resistant to treatment with an EGFR inhibitor.

摘要翻译： 本发明提供了用于确定肿瘤的上皮和间质表型的方法，并且预测肿瘤生长是否对EGFR抑制剂治疗敏感或具有抗性。

公开(公告)号：US11261498B2

公开(公告)日：2022-03-01

申请号：US16591253

申请日：2019-10-02

申请人： Genentech, Inc.

发明人： Thomas E. Januario ,  David Shames

IPC分类号： C12Q1/6886 ,  A61K31/517

摘要： The present invention provides methods of treating cancer based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of administering an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.